Pharmanovia Acquires Exclusive Rights to Treatment for Parkinson’s Disease
10/07/24, 10:06 PM
Location
Industry
biotechnology
health care
Type
agreement
Pharmanovia has announced the expansion of its neurology portfolio with a new licensing agreement for XADAGO® (safinamide), an add-on treatment for adult patients with idiopathic Parkinson's disease.
Company Info
Location
basildon, essex, united kingdom
Additional Info
Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.
We do this by rediscovering, repurposing or re-engineering established medicines to improve patient outcomes and experiences as well as identifying new chemical entities that complement our existing portfolio to address unmet need.
With a diverse and growing team in over 160 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.
Related People

Unlock Verified Contacts + AI Outreach
Instantly access verified contact emails — and let Fundz AI draft a hyper-personalized message based on their role, company, and your company's offering.
Nh
Nh • Executive
Email hidden • Upgrade to unlock
Trusted by teams at Google, Oracle, HubSpot & more